B-cell lymphoma is a group of hematological malignancies characterized by variable genetic and biological features and clinical behaviors.The tumor microenvironment(TME)is a complex network in tumors,which consists of surrounding blood vessels,extracellular matrix,immune and non-immune cells,and signaling molecules.Increasing evidence has shown that the TME,espe-cially immune cells within,is a double-edged sword,acting either as a tumor killer or as a promoter of tumor progression.These pro-tumor activities are driven by subpopulations of immune cells that express typical markers but have unique transcriptional characteristics,making tumor-associated immune cells good targets for human anti-cancer therapy by ablating immunosuppres-sive cells or enhancing immune-activated cells.Thus,exploring the role of immune cells in the TME provides distinct insights for immunotherapy in B-cell lymphoma.In this review,we elucidated the interaction between immune cells and tumor cells and their function in the initiation,progression,and prognosis of B-cell lymphoma,from preclinical experiments to clinical trials.Furthermore,we outlined potential therapeutic approaches and discussed the potential clinical value and future perspectives of targeting immune cells in patients with B-cell lymphoma.
Wenli Zhang;Mengmeng Liu;Wei Li;Yongping Song
Department of Hematology,The First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan 450052,China||Department of Hematology,Henan Provincial Hematology Hospital,Zhengzhou,Henan 450000,China||Academy of Medical Sciences,Zhengzhou University,Zhengzhou,Henan 450052,ChinaAcademy of Medical Sciences,Zhengzhou University,Zhengzhou,Henan 450052,China||Department of Research and Foreign Affairs,The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital,Zhengzhou,Henan 450008,ChinaDepartment of Hematology,The First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan 450052,China||Department of Hematology,Henan Provincial Hematology Hospital,Zhengzhou,Henan 450000,China
Tumor microenvironment;B-cell lymphoma;Immune cells;Immunotherapy;Targeted therapy
《中华医学杂志（英文版）》 2024 (007)
776-790 / 15
This work was supported by Natural Science Foundation of China(No.82270149),China Postdoctoral Science Foundation(Nos.2022T150592 and 2021M692930)and Young Postdoctoral Innovators in Henan Province(WL).Major Project of Henan Medical Science and Technology Research Plan(No.SBGJ202101007).Henan Province Medical Science and Technology Research Project(No.LHGJ20220305).
10.1097/CM9.0000000000002919
评论